Resplit bei Genocea Biosciences

Zahlen für Q3/19

www.sec.gov/Archives/edgar/data/1457612/...a-20190930x10q.htm

Zahlen für Q1/20

• keine Umsätze
  
• Verlust 13 Mio. $
  
• Cash 27 Mio.$
  
• Cashreichweite ~2 Quartale
  
• MK 59 Mio. $
  

"Genocea expects that its existing cash and cash equivalents are sufficient to support its operations into the first quarter of 2021."

ir.genocea.com/news-releases/...quarter-2020-corporate-update

Zahlen für Q2/20

• Umsatz ~1 Mio. $
  
• Verlust 11 Mio. $
  
• Cash 22 Mio. $
  
• MK 99 Mio. $ (vor Abschluss der PP)
  
• 22/07/20 Privatplatzierung bis zu 80 Mio. $
  
  • 21,4 Mio. Aktien
    
  • 12,2 Mio. pre-funded warrants (zu 2,25$)
    
• Upcoming GEN-009 data update planned for July 30th
  

ir.genocea.com/news-releases/...lacement-financing-80-million

"Genocea expects that its existing cash and cash equivalents inclusive of the private placement proceeds are sufficient to support its operations to mid-2022."

ir.genocea.com/news-releases/...quarter-2020-corporate-update

Phase 1/2A GEN-009

ir.genocea.com/news-releases/...-009-neoantigen-vaccine-phase

Zahlen für Q3/20

• Umsätze 0,5 Mio. $
  
• oper. Verlust 11 Mio. $
  
• Cash 88 Mio. $
  
• MK 105 Mio. $
  

Genocea expects that its existing cash and cash equivalents are sufficient to support its operations to mid-2022.

ir.genocea.com/news-releases/...quarter-2020-corporate-update

Zahlen für Q2/21

• keine Umsätze
  
• oper. Verlust 15 Mio. $
  
• Cash 60 Mio. $
  
• MK 102 Mio. $
  

Genocea’s operating plan extends its cash runway to the end of 2022

ir.genocea.com/news-releases/...quarter-2021-corporate-update

Zahlen für Q3/21

• Umsatz 1,6 Mio. $
  
• operativer Verlust 12 Mio. $
  
• Cash 49 Mio. $
  
• MK 58 Mio. $
  

ir.genocea.com/news-releases/...quarter-2021-corporate-update